Search
Sign In
Sign In
Sources
7 Total Sources
Daraxonrasib Shrinks Tumors in 30% of 136 Lung Cancer Patients After Early Trial
All
7
Left
1
Center
1
Others
5
abcnews.com
69d ago
Early Study Suggests Daraxonrasib Reduces Tumors in Lung Cancer Patients
Forbes
69d ago
Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial
vastkind.com
66d ago
Daraxonrasib Shrinks Lung Tumors. Can It Buy More Time?
Oncodaily
67d ago
Eileen M. O’Reilly and RASolute 302: A Rare Survival Advance in Pancreatic Cancer - OncoDaily
Facebook
69d ago
Daraxonrasib for KRAS G12C-mutated non-small cell lung cancer treatment
threads.com
69d ago
In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients
Yahoo News UK
69d ago
Breakthrough Pancreatic Cancer Drug Shows Promise In Lung Cancer Trial - Yahoo News UK